此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

GSK4527363 在健康参与者、系统性红斑狼疮 (SLE) 参与者以及健康中国和日本参与者中的研究

2026年11月11日 更新者:GlaxoSmithKline

一项首次人体三部分研究,旨在评估 GSK4527363 在健康参与者(A 部分)、活动性系统性红斑狼疮参与者(B 部分)中的安全性、耐受性、药代动力学、药效学和免疫原性,华裔和日本裔健康参与者(C 部分)

This study will assess the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of GSK4527363 in healthy participants (Part A), participants with active SLE (Part B), healthy participants of Chinese and Japanese descent (Part C), and participants with interstitial lung disease associated with connective tissue disease (Part D)

研究概览

研究类型

介入性

注册 (实际的)

143

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Juiz de Fora、巴西、36010-570
        • GSK Investigational Site
      • Porto Alegre、巴西、90480000
        • GSK Investigational Site
      • Salvador、巴西、40050-410
        • GSK Investigational Site
    • Rio Grande do Sul
      • Porto Alegre、Rio Grande do Sul、巴西、90035-903
        • GSK Investigational Site
      • Bydgoszcz、波兰、85-065
        • GSK Investigational Site
      • Poznan、波兰、61-848
        • GSK Investigational Site
      • Warsaw、波兰、02-665
        • GSK Investigational Site
      • Wroclaw、波兰、50-556
        • GSK Investigational Site
    • Nevada
      • Las Vegas、Nevada、美国、89154
        • GSK Investigational Site
    • Ohio
      • Columbus、Ohio、美国、44109
        • GSK Investigational Site
      • Cambridge、英国、CB2 0GG
        • GSK Investigational Site
      • Liverpool、英国、L7 8YE
        • GSK Investigational Site
      • London、英国、SW3 6HP
        • GSK Investigational Site
      • Middlesex、英国、HA1 3UJ
        • GSK Investigational Site
      • Barcelona、西班牙、08916
        • GSK Investigational Site
      • Bilbao、西班牙、48013
        • GSK Investigational Site
      • Sabadell Barcelona、西班牙、08208
        • GSK Investigational Site
      • Valladolid、西班牙、47012
        • GSK Investigational Site
    • Navarre
      • Pamplona Iruna、Navarre、西班牙、31008
        • GSK Investigational Site
      • Buenos Aires、阿根廷、C1280AEB
        • GSK Investigational Site
      • Rosario、阿根廷、S2002
        • GSK Investigational Site
      • San Juan Bautista、阿根廷、B1888AAE
        • GSK Investigational Site
      • San Miguel de Tucumán、阿根廷、T4000IHE
        • GSK Investigational Site

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 65年 (成人、年长者)

接受健康志愿者

是的

有资格学习的性别

全部

描述

Inclusion criteria:

For Part A and Part C (Healthy Participants):

  • Participant must be 18 to 55 years of age inclusive, at the time of signing the informed consent form
  • Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring (vital signs and 12-lead ECG)
  • Part C only: Be of Japanese (Cohort C1) or Chinese (Cohort C2) ancestry i. Born in Japan (Cohort C1) or China mainland, Hong Kong or Taiwan (Cohort C2); and ii. Descendent of 2 ethnic Japanese (Cohort C1) or Chinese (Cohort C2) parents and 4 ethnic grandparents; and iii. Have lived outside Japan (Cohort C1) or China mainland, Hong Kong or Taiwan (Cohort C2) for less than 10 years at the time of screening
  • Body weight greater than or equals to (>=) 45 kilograms (kg)
  • Body mass index (BMI) within the range 18-32 kilograms per square meter (kg/m^2) (inclusive)
  • Male or female of non-childbearing potential

For Part B (SLE participants):

  • 18 to 65 years of age inclusive, at the time of signing the informed consent form
  • Documented clinical diagnosis of SLE according to the (European alliance of associations of rheumatology [EULAR]/ American College of Rheumatology [ACR] SLE classification criteria)
  • Body weight >= 45 kg
  • BMI within the range 18-32 kg/m^2 (inclusive)
  • Male or female
  • Capable of giving signed informed consent For Part D (CTD-ILD Participants)
  • Participants must be 18 to 65 years of age, at the time of signing the informed consent form
  • Documented clinical diagnosis of specific Connective Tissue Diseases in accordance with internationally recognised classification criteria
  • Documented clinical diagnosis of interstitial lung disease (ILD) as determined by historical High-resolution computed tomography (HRCT)
  • Participants must be on a stable dose of therapy to manage ILD and/or underlying connective tissue disease (CTD)
  • Body weight >= 45 kg
  • BMI within the range 18-32 kg/m^2 (inclusive)
  • Male or female
  • Capable of giving signed informed consent

Exclusion criteria:

For Part A and Part C (Healthy Participants):

  • History or presence or cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematologic, or neurological disorders
  • A history of recurrent infections, or treatment of a chronic infection within 3 months prior to the first dose of study drug
  • Any acute infection (including upper respiratory tract infections and urinary tract infections) which has not fully resolved within four weeks before dosing
  • Symptomatic herpes zoster within 3 months prior to screening
  • Have a history of malignancy, or a strong family history of malignancies related to immunosuppression
  • Clinically significant multiple or severe drug allergies, intolerance to topical corticosteroids, or severe post-treatment hypersensitivity reactions
  • Abnormal blood pressure
  • Evidence of active or latent Tuberculosis (TB)
  • Alanine transaminase (ALT) >=1.1* Upper limit of normal (ULN)
  • Total bilirubin >1.0*ULN; Participants with Gilbert's syndrome can be included with total bilirubin >=1.5*ULN as long as direct bilirubin is less than or equal to (<=)1.5*ULN
  • Presence of Hepatitis B surface antigen (HBsAg) and Hepatitis B core antibody (HBcAb) at screening or within 3 months prior to first dose of study intervention
  • Positive hepatitis C antibody test result at screening or within 3 months prior to first dose of study intervention
  • Positive Hepatitis C Ribonucleic acid (RNA) test result at screening or within 3 months prior to first dose of study intervention
  • Positive Human immunodeficiency virus (HIV) antibody test at screening
  • Prior medical history of anaphylaxis
  • QT interval corrected for heart rate according to Fridericia's formula (QTcF) >450 milliseconds (msec)
  • Live vaccine(s) within 30 days before the dosing day or plans to receive such vaccines during the study

For Part B (SLE participants):

  • Any acute, severe lupus related flare during the Screening Period that needs immediate treatment

  • Have clinical evidence of significant unstable or uncontrolled acute or chronic diseases not due to SLE which, in the opinion of the principal investigator (PI), could confound the results of the clinical study or put the participant at undue risk

  • Have an acute or chronic infection requiring management as follows:

    i. Currently on any suppressive therapy for a chronic infection such as pneumocystis, cytomegalovirus, herpes simplex virus, herpes zoster, or atypical mycobacteria ii. A serious infection requiring treatment with antibiotics and/or hospitalization if the last dose of antibiotics or the hospital discharge date was within 60 days of the first day of dosing (Day 1). Prophylactic anti-infective treatment is allowed

  • Evidence of active or latent TB

  • Confirmed Progressive Multifocal Leukoencephalopathy (PML) or unexplained new-onset or deteriorating neurologic signs and symptoms

  • ALT >2*ULN

  • Total bilirubin >1.5*ULN; Participants with Gilbert's syndrome can be included with total bilirubin >1.5*ULN as long as direct bilirubin is >1.5*ULN

  • Presence of HBsAg and/or HBcAb at screening or within 3 months prior to first dose of study intervention

  • Positive hepatitis C antibody test result at screening or within 3 months prior to first dose of study intervention

  • Positive hepatitis C RNA test result at screening or within 3 months prior to first dose of study intervention

  • History or positive test at Screening for HIV

  • QTcF >450 msec

  • Solid or hematological malignancy or a history of malignancy (in the past 5 years) of except for basal cell or squamous cell in situ skin carcinomas, Cervical intraepithelial neoplasia (CIN) or carcinoma in situ of the cervix that have been resected with no evidence of metastatic disease for 3 years

  • Live or live-attenuated vaccine(s) within 30 days prior to Screening

For Part D Participants:

  • A diagnosis of: ILD other than CTD-ILD and/or SLE
  • FVC <= 45% predicted at Screening Pulmonary arterial hypertension, as determined by the Investigator, prior to Day 1
  • Major surgery (including joint surgery) within 3 months prior to Screening or planned during the duration of the study
  • Previous or planned major organ transplant (e.g. heart, lung, kidney, liver) or bone marrow transplant (e.g. autologous stem cell transplant)
  • Have clinical evidence of significant unstable or uncontrolled acute or chronic diseases not due to CTD-ILD (i.e., cardiovascular, metabolic, hematologic, GI, hepatic, renal, neurological, psychiatric, malignancy, or infectious diseases) which, in the opinion of the PI, could confound the results of the clinical study or put the participant at undue risk
  • Have an acute or chronic infection including requiring management
  • Evidence of active or latent TB
  • Confirmed PML or unexplained new-onset or deteriorating neurologic signs and symptoms
  • ALT >2*ULN
  • Total bilirubin >1.5*ULN; Participants with Gilbert's syndrome can be included with total bilirubin >1.5*ULN as long as direct bilirubin is >1.5*ULN
  • Presence of HBsAg and/or HBcAb at screening or within 3 months prior to first dose of study intervention
  • Positive hepatitis C antibody test result at screening or within 3 months prior to first dose of study intervention
  • Positive hepatitis C RNA test result at screening or within 3 months prior to first dose of study intervention
  • History or positive test at Screening for HIV
  • Solid or hematological malignancy or a history of malignancy (in the past 5 years) of except for basal cell or squamous cell in situ skin carcinomas, CIN or carcinoma in situ of the cervix that have been resected with no evidence of metastatic disease for 3 years
  • Live or live-attenuated vaccine(s) within 30 days prior to Screening or plans to receive such vaccines during the Screening period or during the clinical study

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:双倍的

武器和干预

参与者组/臂
干预/治疗
实验性的:A 部分:接受 GSK4527363 的健康参与者

GSK4527363 will be administered to participants.

安慰剂比较:A 部分:健康参与者接受与 GSK4527363 匹配的安慰剂

Placebo matching GSK4527363 will be administered to participants.

实验性的:A 部分:接受贝利尤单抗治疗的健康参与者

Belimumab will be administered to participants.

实验性的:B 部分:患有 SLE 的参与者接受 GSK4527363

GSK4527363 will be administered to participants.

实验性的:B 部分:患有 SLE 的参与者接受贝利尤单抗治疗

Belimumab will be administered to participants.

实验性的:C 部分:健康的日本参与者接受 GSK4527363

GSK4527363 will be administered to participants.

安慰剂比较:C 部分:健康的日本参与者接受与 GSK4527363 匹配的安慰剂

Placebo matching GSK4527363 will be administered to participants.

实验性的:C 部分:健康的中国参与者接受 GSK4527363

GSK4527363 will be administered to participants.

安慰剂比较:C 部分:健康的中国参与者接受与 GSK4527363 匹配的安慰剂

Placebo matching GSK4527363 will be administered to participants.

实验性的:D部分:接受GSK4527363治疗的CTD-ILD参与者

GSK4527363 will be administered to participants.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
A 部分和 C 部分:出现非严重不良事件和严重不良事件的参与者人数
大体时间:最长至第52周
最长至第52周
B部分和D部分:出现非严重不良事件和严重不良事件的参与者人数
大体时间:直至第68周
直至第68周
A部分和C部分:在体检、实验室参数、生命体征和12导联心电图(ECG)结果中出现临床意义变化的参与者人数
大体时间:直至第52周
直至第52周
B部分和D部分:在体格检查、实验室参数、生命体征和12导联心电图(ECG)结果中具有临床意义变化的参与者人数
大体时间:截至第68周
截至第68周
Parts A and C: Number of Participants with Clinically Significant Changes in Columbia-Suicide Severity Rating Scale (C-SSRS)
大体时间:Up to Week 52

The C-SSRS is an assessment tool that evaluates suicidal ideation and behavior. A suicidal ideation score will be calculated based on the maximum suicidal ideation category ranging from 1 to 5. Higher score indicates more suicidal ideation. A clinically important change in the C-SSRS is defined as a total score >0.

Up to Week 52
Parts B, and D: Number of Participants with Clinically Significant Changes in Columbia-Suicide Severity Rating Scale (C-SSRS)
大体时间:Up to Week 68

The C-SSRS is an assessment tool that evaluates suicidal ideation and behavior. A suicidal ideation score will be calculated based on the maximum suicidal ideation category ranging from 1 to 5. Higher score indicates more suicidal ideation. A clinically important change in the C-SSRS is defined as a total score >0.

Up to Week 68

次要结果测量

结果测量
大体时间
A部分和C部分:GSK4527363从给药至最后可定量浓度时间点的浓度-时间曲线下面积(AUC[0-t])
大体时间:至第52周
至第52周
A部分和C部分:GSK4527363从零时至无限时的浓度-时间曲线下面积(AUC[0-inf])
大体时间:至第52周
至第52周
A 部分和 C 部分:GSK4527363 的最大血浆浓度 (Cmax)
大体时间:长达第52周
长达第52周
A部分和C部分:GSK4527363的表观终末相半衰期(t1/2)
大体时间:截至第 52 周
截至第 52 周
A、B和C部分:针对GSK4527363的ADA滴度
大体时间:至第52周
至第52周
A部分和C部分:针对GSK4527363的抗药抗体(ADA)阳性的受试者数量
大体时间:截至第 52 周
截至第 52 周
B部分和D部分:具有针对GSK4527363的抗药物抗体(ADAs)的参与者人数
大体时间:截至第68周
截至第68周
A部分和C部分:细胞因子水平相对于基线的百分比变化
大体时间:基线(第1天)至第52周
基线(第1天)至第52周
B部分和D部分:细胞因子相对于基线的百分比变化
大体时间:基线(第1天)至第68周
基线(第1天)至第68周
B部分和D部分:GSK4527363浓度-时间曲线下面积
大体时间:截至第12周
截至第12周
Part B and D: GSK4527363 的最大血浆浓度
大体时间:直至第12周
直至第12周
Part B and D: GSK4527363 首次给药间隔结束时的浓度
大体时间:截至第12周
截至第12周

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 研究主任:GSK Clinical Trials、GlaxoSmithKline

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2024年9月2日

初级完成 (估计的)

2028年2月1日

研究完成 (估计的)

2028年2月1日

研究注册日期

首次提交

2024年8月26日

首先提交符合 QC 标准的

2024年8月26日

首次发布 (实际的)

2024年8月28日

研究记录更新

最后更新发布 (实际的)

2026年11月12日

上次提交的符合 QC 标准的更新

2026年11月11日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk-studyregister.com/gsk-patient-level-data-sharing-july2025.pdf

IPD 共享时间框架

Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.

IPD 共享访问标准

Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.

IPD 共享支持信息类型

  • 研究方案
  • 树液
  • 国际碳纤维联合会
  • 企业社会责任

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅